A related compound, esketamine, has been approved in the European Union and the United States for the emergency treatment of treatment-resistant depression, administered as a nasal spray under strict ...

The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working ...